Cover Page
Cover Page - shares | 9 Months Ended | |
Jan. 31, 2022 | Mar. 08, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jan. 31, 2022 | |
Document Transition Report | false | |
Entity File Number | 0-5286 | |
Entity Registrant Name | KEWAUNEE SCIENTIFIC CORP /DE/ | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 38-0715562 | |
Entity Address, Address Line One | 2700 West Front Street | |
Entity Address, City or Town | Statesville, | |
Entity Address, State or Province | NC | |
Entity Address, Postal Zip Code | 28677-2927 | |
City Area Code | 704 | |
Local Phone Number | 873-7202 | |
Title of 12(b) Security | Common Stock, $2.50 par value | |
Trading Symbol | KEQU | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 2,789,873 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Entity Central Index Key | 0000055529 | |
Current Fiscal Year End Date | --04-30 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | |
Income Statement [Abstract] | ||||
Net sales | $ 40,633 | $ 33,339 | $ 119,157 | $ 108,762 |
Cost of products sold | 35,011 | 27,685 | 104,264 | 90,832 |
Gross profit | 5,622 | 5,654 | 14,893 | 17,930 |
Operating expenses | 6,490 | 6,030 | 19,742 | 18,593 |
Operating loss | (868) | (376) | (4,849) | (663) |
Pension income (expense) | 88 | (288) | 266 | (865) |
Other income, net | 51 | 51 | 149 | 171 |
Interest expense | (158) | (105) | (396) | (310) |
Loss before income taxes | (887) | (718) | (4,830) | (1,667) |
Income tax expense (benefit) | 399 | (813) | 845 | (989) |
Net (loss) earnings | (1,286) | 95 | (5,675) | (678) |
Less: Net earnings attributable to the non-controlling interest | 33 | 14 | 89 | 19 |
Net (loss) earnings attributable to Kewaunee Scientific Corporation | $ (1,319) | $ 81 | $ (5,764) | $ (697) |
Net (loss) earnings per share attributable to Kewaunee Scientific Corporation stockholders | ||||
Basic (in dollars per share) | $ (0.47) | $ 0.03 | $ (2.07) | $ (0.25) |
Diluted (in dollars per share) | $ (0.47) | $ 0.03 | $ (2.07) | $ (0.25) |
Weighted average number of common shares outstanding | ||||
Basic (in shares) | 2,790 | 2,762 | 2,785 | 2,759 |
Diluted (in shares) | 2,790 | 2,789 | 2,785 | 2,759 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | ||||
Net (loss) earnings | $ (1,286) | $ 95 | $ (5,675) | $ (678) |
Other comprehensive (loss) income, net of tax: | ||||
Foreign currency translation adjustments | 52 | 31 | (107) | (17) |
Other comprehensive (loss) income | 52 | 31 | (107) | (17) |
Comprehensive (loss) income, net of tax | (1,234) | 126 | (5,782) | (695) |
Less: Comprehensive income attributable to the non-controlling interest | 33 | 14 | 89 | 19 |
Comprehensive (loss) income attributable to Kewaunee Scientific Corporation | $ (1,267) | $ 112 | $ (5,871) | $ (714) |
Condensed Consolidated Statem_3
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Loss |
Beginning balance at Apr. 30, 2020 | $ 38,415 | $ 6,885 | $ 3,360 | $ (53) | $ 37,821 | $ (9,598) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss attributable to Kewaunee Scientific Corporation | (598) | (598) | ||||
Other comprehensive loss | (13) | (13) | ||||
Stock-based compensation | 98 | 20 | 78 | |||
Ending balance at Jul. 31, 2020 | 37,902 | 6,905 | 3,438 | (53) | 37,223 | (9,611) |
Beginning balance at Apr. 30, 2020 | 38,415 | 6,885 | 3,360 | (53) | 37,821 | (9,598) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss attributable to Kewaunee Scientific Corporation | (697) | |||||
Other comprehensive loss | (17) | |||||
Ending balance at Jan. 31, 2021 | 38,055 | 6,915 | 3,684 | (53) | 37,124 | (9,615) |
Beginning balance at Jul. 31, 2020 | 37,902 | 6,905 | 3,438 | (53) | 37,223 | (9,611) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss attributable to Kewaunee Scientific Corporation | (180) | (180) | ||||
Other comprehensive loss | (35) | (35) | ||||
Stock-based compensation | 143 | 0 | 143 | |||
Ending balance at Oct. 31, 2020 | 37,830 | 6,905 | 3,581 | (53) | 37,043 | (9,646) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss attributable to Kewaunee Scientific Corporation | 81 | 81 | ||||
Other comprehensive loss | 31 | 31 | ||||
Stock-based compensation | 113 | 10 | 103 | |||
Ending balance at Jan. 31, 2021 | 38,055 | 6,915 | 3,684 | (53) | 37,124 | (9,615) |
Beginning balance at Apr. 30, 2021 | 41,241 | 6,915 | 3,807 | (53) | 34,149 | (3,577) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss attributable to Kewaunee Scientific Corporation | (1,345) | (1,345) | ||||
Other comprehensive loss | (76) | (76) | ||||
Stock-based compensation | 238 | 67 | 171 | |||
Ending balance at Jul. 31, 2021 | 40,058 | 6,982 | 3,978 | (53) | 32,804 | (3,653) |
Beginning balance at Apr. 30, 2021 | 41,241 | 6,915 | 3,807 | (53) | 34,149 | (3,577) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss attributable to Kewaunee Scientific Corporation | (5,764) | |||||
Other comprehensive loss | (107) | |||||
Ending balance at Jan. 31, 2022 | 35,847 | 6,983 | 4,216 | (53) | 28,385 | (3,684) |
Beginning balance at Jul. 31, 2021 | 40,058 | 6,982 | 3,978 | (53) | 32,804 | (3,653) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss attributable to Kewaunee Scientific Corporation | (3,100) | (3,100) | ||||
Other comprehensive loss | (83) | (83) | ||||
Stock-based compensation | 130 | 1 | 129 | |||
Ending balance at Oct. 31, 2021 | 37,005 | 6,983 | 4,107 | (53) | 29,704 | (3,736) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss attributable to Kewaunee Scientific Corporation | (1,319) | (1,319) | ||||
Other comprehensive loss | 52 | 52 | ||||
Stock-based compensation | 109 | 109 | ||||
Ending balance at Jan. 31, 2022 | $ 35,847 | $ 6,983 | $ 4,216 | $ (53) | $ 28,385 | $ (3,684) |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jan. 31, 2022 | Apr. 30, 2021 |
Current Assets: | ||
Cash and cash equivalents | $ 4,697 | $ 5,206 |
Restricted cash | 805 | 525 |
Receivables, less allowance; $426; $636, on each respective date | 35,053 | 32,882 |
Inventories | 19,947 | 16,517 |
Income tax receivable | 638 | 955 |
Prepaid expenses and other current assets | 7,780 | 4,372 |
Total Current Assets | 68,920 | 60,457 |
Property, plant and equipment, at cost | 60,269 | 58,804 |
Accumulated depreciation | (44,924) | (42,822) |
Net Property, Plant and Equipment | 15,345 | 15,982 |
Right of use assets | 8,006 | 9,279 |
Other assets | 3,415 | 3,666 |
Total Assets | 95,686 | 89,384 |
Current Liabilities: | ||
Short-term borrowings | 8,962 | 6,828 |
Current portion of financing lease liability | 131 | 21 |
Current portion of operating lease liabilities | 1,355 | 1,348 |
Accounts payable | 27,415 | 16,780 |
Employee compensation and amounts withheld | 4,930 | 4,726 |
Deferred revenue | 3,104 | 3,123 |
Other accrued expenses | 1,611 | 1,355 |
Total Current Liabilities | 47,508 | 34,181 |
Long-term portion of financing lease liability | 198 | 91 |
Long-term portion of operating lease liabilities | 6,605 | 7,860 |
Accrued pension and deferred compensation costs | 4,381 | 4,652 |
Deferred income taxes | 411 | 307 |
Other non-current liabilities | 403 | 806 |
Total Liabilities | 59,506 | 47,897 |
Commitments and Contingencies | ||
Stockholders' Equity: | ||
Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,793 shares; 2,766 shares; – Outstanding – 2,790 shares; 2,763 shares, on each respective date | 6,983 | 6,915 |
Additional paid-in-capital | 4,216 | 3,807 |
Retained earnings | 28,385 | 34,149 |
Accumulated other comprehensive loss | (3,684) | (3,577) |
Common stock in treasury, at cost, 3 shares, on each respective date | (53) | (53) |
Total Kewaunee Scientific Corporation Stockholders' Equity | 35,847 | 41,241 |
Non-controlling interest | 333 | 246 |
Total Stockholders' Equity | 36,180 | 41,487 |
Total Liabilities and Stockholders' Equity | $ 95,686 | $ 89,384 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands | Jan. 31, 2022 | Apr. 30, 2021 |
Current Assets: | ||
Allowance for receivables | $ 426 | $ 636 |
Stockholders' Equity: | ||
Common stock, par value (in dollars per share) | $ 2.50 | $ 2.50 |
Common stock, shares authorized (in shares) | 5,000 | 5,000 |
Common stock, shares issued (in shares) | 2,793 | 2,766 |
Common stock, shares outstanding (in shares) | 2,790 | 2,763 |
Treasury stock, shares (in shares) | 3 | 3 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Jan. 31, 2022 | Jan. 31, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (5,675) | $ (678) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||
Depreciation | 2,092 | 2,005 |
Bad debt provision | 27 | 60 |
Stock-based compensation expense | 502 | 385 |
Deferred income taxes | 104 | 159 |
Change in assets and liabilities: | ||
Receivables | (2,199) | (2,318) |
Inventories | (3,430) | (285) |
Income tax receivable | 316 | (1,488) |
Accounts payable and other accrued expenses | 10,692 | 3,843 |
Deferred revenue | (19) | 1,134 |
Other, net | (3,497) | 290 |
Net cash (used in) provided by operating activities | (1,087) | 3,107 |
Cash flows from investing activities: | ||
Capital expenditures | (1,222) | (1,944) |
Net cash used in investing activities | (1,222) | (1,944) |
Cash flows from financing activities: | ||
Dividends paid to non-controlling interest in subsidiaries | 0 | (108) |
Proceeds from short-term borrowings | 42,975 | 49,298 |
Repayments on short-term borrowings | (40,840) | (49,524) |
Payments on long-term lease obligations | (16) | (14) |
Net proceeds from exercise of stock options | 0 | (31) |
Net cash provided by (used in) financing activities | 2,119 | (379) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (39) | 104 |
(Decrease) increase in cash, cash equivalents and restricted cash | (229) | 888 |
Cash, cash equivalents and restricted cash, beginning of period | 5,731 | 5,215 |
Cash, cash equivalents and restricted cash, end of period | $ 5,502 | $ 6,103 |
Financial Information
Financial Information | 9 Months Ended |
Jan. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Financial Information | Financial Information The unaudited interim Condensed Consolidated Financial Statements of Kewaunee Scientific Corporation (the "Company") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "Commission"). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading. These interim Condensed Consolidated Financial Statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's 2021 Annual Report on Form 10-K . The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The Condensed Consolidated Balance Sheet as of April 30, 2021 included in this interim period filing has been derived from the audited consolidated financial statements at that date, but does not include all of the information and related notes required by GAAP for complete financial statements. The preparation of the interim Condensed Consolidated Financial Statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. |
Cash, Cash Equivalents and Rest
Cash, Cash Equivalents and Restricted Cash | 9 Months Ended |
Jan. 31, 2022 | |
Cash and Cash Equivalents [Abstract] | |
Cash, Cash Equivalents and Restricted Cash | Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less. During the periods ended January 31, 2022 and April 30, 2021, the Company had cash deposits in excess of FDIC insured limits. The Company has not experienced any losses from such deposits. Restricted cash includes bank deposits of subsidiaries used for performance guarantees against customer orders. The Company includes restricted cash along with the cash balance for presentation in the Condensed Consolidated Statements of Cash Flows. The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows: January 31, 2022 April 30, 2021 Cash and cash equivalents $ 4,697 $ 5,206 Restricted cash 805 525 Total cash, cash equivalents and restricted cash $ 5,502 $ 5,731 |
Revenue Recognition
Revenue Recognition | 9 Months Ended |
Jan. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition | Revenue RecognitionThe Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company's revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company's revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract. Disaggregated Revenue A summary of net sales transferred to customers over time and at a point in time for the periods ended January 31, 2022 and January 31, 2021 is as follows (in thousands): Three Months Ended January 31, 2022 January 31, 2021 Domestic International Total Domestic International Total Over Time $ 28,240 $ 11,102 $ 39,342 $ 24,198 $ 8,273 $ 32,471 Point in Time 1,291 — 1,291 868 — 868 Total $ 29,531 $ 11,102 $ 40,633 $ 25,066 $ 8,273 $ 33,339 Nine Months Ended January 31, 2022 January 31, 2021 Domestic International Total Domestic International Total Over Time $ 85,342 $ 30,029 $ 115,371 $ 81,206 $ 24,866 $ 106,072 Point in Time 3,786 — 3,786 2,690 — 2,690 Total $ 89,128 $ 30,029 $ 119,157 $ 83,896 $ 24,866 $ 108,762 Contract Balances The closing and opening balances of contract assets included $8,450,000 in accounts receivable and $1,305,000 in other assets at January 31, 2022. The opening balance of contract assets arising from contracts with customers included $5,716,000 in accounts receivable and $1,213,000 in other assets at April 30, 2021. The closing and opening balances of contract liabilities included in deferred revenue arising from contracts with customers were $3,104,000 at January 31, 2022 and $3,123,000 at April 30, 2021. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue which are disclosed in the Condensed Consolidated Balance Sheets and in the Notes to the Condensed Consolidated Financial Statements. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms and are included in receivables on the Condensed Consolidated Balance Sheets. Receivables are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. Approximately 100% of the contract liability balances at April 30, 2021 and January 31, 2022 are expected to be recognized as revenue during the respective succeeding 12 months. |
Inventories
Inventories | 9 Months Ended |
Jan. 31, 2022 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories The Company measures inventory using the first-in, first-out ("FIFO") method at the lower of cost or net realizable value. Inventories consisted of the following (in thousands): January 31, 2022 April 30, 2021 Finished products $ 4,997 $ 2,988 Work in process 2,837 1,832 Raw materials 12,113 11,697 Total $ 19,947 $ 16,517 The Company's International subsidiaries' inventories were $2,238,000 at January 31, 2022 and $2,560,000 at April 30, 2021 and are included in the above tables. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 9 Months Ended |
Jan. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company's financial instruments consist primarily of cash and equivalents, mutual funds, cash surrender value of life insurance policies, and short-term borrowings. The carrying value of these assets and liabilities approximates their fair value. The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2022 and April 30, 2021 (in thousands): January 31, 2022 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,274 $ — $ 1,274 Cash surrender value of life insurance policies (1) — 1,441 1,441 Total $ 1,274 $ 1,441 $ 2,715 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,164 $ 3,164 Total $ — $ 3,164 $ 3,164 April 30, 2021 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,299 $ — $ 1,299 Cash surrender value of life insurance policies (1) — 1,458 1,458 Total $ 1,299 $ 1,458 $ 2,757 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,169 $ 3,169 Total $ — $ 3,169 $ 3,169 (1) The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value. (2) Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits. |
Long-term Debt and Other Credit
Long-term Debt and Other Credit Arrangements | 9 Months Ended |
Jan. 31, 2022 | |
Debt Disclosure [Abstract] | |
Long-term Debt and Other Credit Arrangements | Long-term Debt and Other Credit Arrangements At January 31, 2022, advances of $8.4 million were outstanding under the Company's revolving credit facility, compared to advances of $6.8 million outstanding as of April 30, 2021. The Company had standby letters of credit outstanding of $704,000 at January 31, 2022, unchanged from April 30, 2021. Amounts available under the revolving credit facility were $4.1 million and $7.5 million at January 31, 2022 and April 30, 2021, respectively. On July 30, 2021, the Company entered into a Twelfth Amendment to Credit and Security Agreement (the “Amendment”) with Wells Fargo Bank, National Association (the “Bank”). The Amendment made certain changes to the Credit and Security Agreement, dated as of May 6, 2013, as amended (the “Credit Agreement”), between the Company and the Bank, and to the Revolving Line of Credit Note, dated May 6, 2013, made by the Company and payable to the order of the Bank, as amended (the “Revolving Note”). The changes included (i) extending the maturity date under the Credit Agreement and Revolving Note from July 30, 2021 to April 30, 2022; (ii) removing the minimum EBITDA covenant; (iii) in addition to the existing Minimum Monthly Liquidity requirement as of the end of each calendar month of not less than $2,000,000, adding an additional covenant that the Company will maintain Supplemental Liquidity (as defined in the amended Credit Agreement) as of the first day of each calendar month not less than (a) during the period from August 1, 2021 through December 31, 2021, $1,000,000 and (b) thereafter $1,500,000; and (iv) restating the amended Credit Agreement to reflect all amendments to date. At January 31, 2022 and April 30, 2021, the Company was in compliance with all the financial covenants under its revolving credit facility. During the three months ended January 31, 2022, the supplemental liquidity threshold for the Company, as defined in the Credit Agreement, fell below $3,000,000 for one reporting period. The Company has obtained a waiver of the debt covenant violation that occurred on that date and returned to full compliance for the subsequent months during the period ended January 31, 2022. |
Leases
Leases | 9 Months Ended |
Jan. 31, 2022 | |
Leases [Abstract] | |
Leases | Leases In accordance with ASC 842, "Leases," the Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At January 31, 2022 and April 30, 2021, right-of-use assets totaled $8,006,000 and $9,279,000, respectively. Operating cash paid to settle lease liabilities was $1,515,000 and $1,299,000 for the nine months ended January 31, 2022 and January 31, 2021, respectively. The Company's leases have remaining lease terms of up to 8 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $754,000 and $2,309,000 for the three and nine months ended January 31, 2022, respectively, inclusive of period cost for short-term leases, not included in lease liabilities, of $245,000 and $794,000, respectively. Operating lease expenses were $718,000 and $2,032,000 for the three and nine months ended January 31, 2021, respectively, inclusive of period cost for short-term leases, not included in lease liabilities, of $267,000 and $733,000, respectively. At January 31, 2022, the weighted average remaining lease term for the capitalized operating leases was 5.6 years and the weighted average discount rate was 4.1%. For the financing leases, the weighted average remaining lease term was 4.6 years and the weighted average discount rate was 6.8%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable. Future minimum lease payments under non-cancelable leases as of January 31, 2022, excluding the future minimum lease payments for those leases that have not yet commenced as of January 31, 2022, were as follows: Operating Financing Remainder of fiscal 2022 $ 497 $ 62 2023 1,842 86 2024 1,485 86 2025 1,441 86 2026 1,231 67 Thereafter 2,861 — Total Minimum Lease Payments 9,357 387 Imputed Interest (1,397) (44) Total $ 7,960 $ 343 |
Leases | Leases In accordance with ASC 842, "Leases," the Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At January 31, 2022 and April 30, 2021, right-of-use assets totaled $8,006,000 and $9,279,000, respectively. Operating cash paid to settle lease liabilities was $1,515,000 and $1,299,000 for the nine months ended January 31, 2022 and January 31, 2021, respectively. The Company's leases have remaining lease terms of up to 8 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $754,000 and $2,309,000 for the three and nine months ended January 31, 2022, respectively, inclusive of period cost for short-term leases, not included in lease liabilities, of $245,000 and $794,000, respectively. Operating lease expenses were $718,000 and $2,032,000 for the three and nine months ended January 31, 2021, respectively, inclusive of period cost for short-term leases, not included in lease liabilities, of $267,000 and $733,000, respectively. At January 31, 2022, the weighted average remaining lease term for the capitalized operating leases was 5.6 years and the weighted average discount rate was 4.1%. For the financing leases, the weighted average remaining lease term was 4.6 years and the weighted average discount rate was 6.8%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable. Future minimum lease payments under non-cancelable leases as of January 31, 2022, excluding the future minimum lease payments for those leases that have not yet commenced as of January 31, 2022, were as follows: Operating Financing Remainder of fiscal 2022 $ 497 $ 62 2023 1,842 86 2024 1,485 86 2025 1,441 86 2026 1,231 67 Thereafter 2,861 — Total Minimum Lease Payments 9,357 387 Imputed Interest (1,397) (44) Total $ 7,960 $ 343 |
Earnings Per Share
Earnings Per Share | 9 Months Ended |
Jan. 31, 2022 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share Basic earnings per share is based on the weighted average number of common shares outstanding during the year. Diluted earnings per share reflects the assumed exercise of outstanding options and the conversion of restricted stock units ("RSUs") under the Company's various stock compensation plans, except when RSUs and options have an antidilutive effect. There were 135,435 and 83,910 antidilutive RSUs and options outstanding at January 31, 2022 and January 31, 2021, respectively. The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands): Three Months Ended Nine Months Ended January 31, 2022 January 31, 2021 January 31, 2022 January 31, 2021 Basic 2,790 2,762 2,785 2,759 Dilutive effect of stock options and RSUs — 27 — — Weighted average common shares outstanding - diluted 2,790 2,789 2,785 2,759 |
Stock Options and Stock-based C
Stock Options and Stock-based Compensation | 9 Months Ended |
Jan. 31, 2022 | |
Equity [Abstract] | |
Stock Options and Stock-based Compensation | Stock Options and Stock-based Compensation Under ASC 718, "Compensation-Stock Compensation," compensation costs related to stock options and other stock awards granted by the Company are charged against operating expenses during their vesting period. In June 2021, the Company granted 5,500 RSUs under the 2017 Omnibus Incentive Plan ("2017 Plan"). These RSUs include a service component that vests over a two-year period. The Company also granted 51,471 RSUs under the 2017 Omnibus Incentive Plan in June 2021 that include a service component that vests over a three-year period. The recognized expense is |
Income Taxes
Income Taxes | 9 Months Ended |
Jan. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | . Income Taxes Income tax expense of $399,000 and $845,000 was recorded for the three and nine months ended January 31, 2022, respectively. Income tax benefit of $813,000 and $989,000 was recorded for the three and nine months ended January 31, 2021, respectively. The effective tax rates were (45.0)% and (17.5)% for the three and nine months ended January 31, 2022, respectively. The effective tax rates were 113.2% and 59.3% for the three and nine months ended January 31, 2021, respectively. The change in the effective tax rate for the three- and nine-month periods is primarily due to the impact of foreign operations which are taxed at different rates than the U.S. tax rate of 21% and the recording of a valuation allowance against the deferred tax asset which resulted in the elimination of any U.S. income tax benefit. In August 2019, the Company revoked its indefinite reinvestment of foreign unremitted earnings position in compliance with ASC 740 "Income Taxes" and terminated its indefinite reinvestment of unremitted earnings assertion for the Singapore, China, and Kewaunee Labway India Pvt. Ltd. international subsidiaries. The Company has a deferred tax liability of $895,000 and $776,000 for the withholding tax related to Kewaunee Labway India Pvt. Ltd. as of January 31, 2022 and April 30, 2021, respectively. The Company recorded all deferred tax assets and liabilities related to its outside basis differences in its foreign subsidiaries consistent with ASC 740. |
Defined Benefit Pension Plans
Defined Benefit Pension Plans | 9 Months Ended |
Jan. 31, 2022 | |
Retirement Benefits [Abstract] | |
Defined Benefit Pension Plans | Defined Benefit Pension Plans The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. There were no Company contributions paid to the plans for the three and nine months ended January 31, 2022 and January 31, 2021. The Company assumed an expected long-term rate of return of 7.75% for the periods ended January 31, 2022 and January 31, 2021. Pension (income) / expense consisted of the following (in thousands): Three Months Ended January 31, 2022 January 31, 2021 Service cost $ 0 $ 0 Interest cost 177 181 Expected return on plan assets (401) (321) Recognition of net loss 136 428 Net periodic pension (income) expense $ (88) $ 288 Nine Months Ended January 31, 2022 January 31, 2021 Service cost $ 0 $ 0 Interest cost 531 543 Expected return on plan assets (1,203) (963) Recognition of net loss 406 1,285 Net periodic pension (income) expense $ (266) $ 865 |
Segment Information
Segment Information | 9 Months Ended |
Jan. 31, 2022 | |
Segment Reporting [Abstract] | |
Segment Information | Segment Information The Company's operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company's foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments. The following tables provide financial information by business segments for the periods ended January 31, 2022 and 2021 (in thousands): Domestic International Corporate / Total Three months ended January 31, 2022 Revenues from external customers $ 29,531 $ 11,102 $ — $ 40,633 Intersegment revenues 194 1,136 (1,330) — Earnings (loss) before income taxes (255) 869 (1,501) (887) Three months ended January 31, 2021 Revenues from external customers $ 25,066 $ 8,273 $ — $ 33,339 Intersegment revenues 463 550 (1,013) — Earnings (loss) before income taxes 206 689 (1,613) (718) Domestic International Corporate / Total Nine Months Ended January 31, 2022 Revenues from external customers $ 89,128 $ 30,029 $ — $ 119,157 Intersegment revenues 539 2,272 (2,811) — Earnings (loss) before income taxes (2,559) 2,111 (4,382) (4,830) Nine Months Ended January 31, 2021 Revenues from external customers $ 83,896 $ 24,866 $ — $ 108,762 Intersegment revenues 1,715 2,460 (4,175) — Earnings (loss) before income taxes 1,794 1,610 (5,071) (1,667) |
New Accounting Standards
New Accounting Standards | 9 Months Ended |
Jan. 31, 2022 | |
Accounting Policies [Abstract] | |
New Accounting Standards | New Accounting StandardsIn June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company will adopt this standard in fiscal year 2024. The Company does not expect the adoption of this standard to have a significant impact on the Company's consolidated financial position or results of operations.In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes ("Topic 740"): Simplifying the Accounting for Income Taxes." This update simplifies the accounting for income taxes through certain targeted improvements to various subtopics within Topic 740. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. The Company adopted this standard effective May 1, 2021. The adoption of this standard did not have a significant impact on the Company's consolidated financial position or results of operations. |
Reclassifications
Reclassifications | 9 Months Ended |
Jan. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Reclassifications | ReclassificationsThe Company reclassified certain amounts in the Condensed Consolidated Balance Sheet for the period ended April 30, 2021 and the Condensed Consolidated Statements of Cash Flows for the nine-month period ended January 31, 2021 to conform to the current period presentation. There was no impact to the Condensed Consolidated Statements of Operations or Condensed Consolidated Statement of Stockholders' Equity. |
New Accounting Standards Signif
New Accounting Standards Significant Accounting Policies (Policies) | 9 Months Ended |
Jan. 31, 2022 | |
Accounting Policies [Abstract] | |
New Accounting Standards | In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company will adopt this standard in fiscal year 2024. The Company does not expect the adoption of this standard to have a significant impact on the Company's consolidated financial position or results of operations.In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes ("Topic 740"): Simplifying the Accounting for Income Taxes." This update simplifies the accounting for income taxes through certain targeted improvements to various subtopics within Topic 740. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. The Company adopted this standard effective May 1, 2021. The adoption of this standard did not have a significant impact on the Company's consolidated financial position or results of operations. |
Cash, Cash Equivalents and Re_2
Cash, Cash Equivalents and Restricted Cash (Tables) | 9 Months Ended |
Jan. 31, 2022 | |
Cash and Cash Equivalents [Abstract] | |
Schedule of Cash, Cash Equivalents, and Restricted Cash | The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows: January 31, 2022 April 30, 2021 Cash and cash equivalents $ 4,697 $ 5,206 Restricted cash 805 525 Total cash, cash equivalents and restricted cash $ 5,502 $ 5,731 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 9 Months Ended |
Jan. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | A summary of net sales transferred to customers over time and at a point in time for the periods ended January 31, 2022 and January 31, 2021 is as follows (in thousands): Three Months Ended January 31, 2022 January 31, 2021 Domestic International Total Domestic International Total Over Time $ 28,240 $ 11,102 $ 39,342 $ 24,198 $ 8,273 $ 32,471 Point in Time 1,291 — 1,291 868 — 868 Total $ 29,531 $ 11,102 $ 40,633 $ 25,066 $ 8,273 $ 33,339 Nine Months Ended January 31, 2022 January 31, 2021 Domestic International Total Domestic International Total Over Time $ 85,342 $ 30,029 $ 115,371 $ 81,206 $ 24,866 $ 106,072 Point in Time 3,786 — 3,786 2,690 — 2,690 Total $ 89,128 $ 30,029 $ 119,157 $ 83,896 $ 24,866 $ 108,762 |
Inventories (Tables)
Inventories (Tables) | 9 Months Ended |
Jan. 31, 2022 | |
Inventory Disclosure [Abstract] | |
Summary of Inventories | Inventories consisted of the following (in thousands): January 31, 2022 April 30, 2021 Finished products $ 4,997 $ 2,988 Work in process 2,837 1,832 Raw materials 12,113 11,697 Total $ 19,947 $ 16,517 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 9 Months Ended |
Jan. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis | The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2022 and April 30, 2021 (in thousands): January 31, 2022 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,274 $ — $ 1,274 Cash surrender value of life insurance policies (1) — 1,441 1,441 Total $ 1,274 $ 1,441 $ 2,715 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,164 $ 3,164 Total $ — $ 3,164 $ 3,164 April 30, 2021 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,299 $ — $ 1,299 Cash surrender value of life insurance policies (1) — 1,458 1,458 Total $ 1,299 $ 1,458 $ 2,757 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,169 $ 3,169 Total $ — $ 3,169 $ 3,169 (1) The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value. (2) Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits. |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Jan. 31, 2022 | |
Leases [Abstract] | |
Schedule of Operating Lease Maturity | Future minimum lease payments under non-cancelable leases as of January 31, 2022, excluding the future minimum lease payments for those leases that have not yet commenced as of January 31, 2022, were as follows: Operating Financing Remainder of fiscal 2022 $ 497 $ 62 2023 1,842 86 2024 1,485 86 2025 1,441 86 2026 1,231 67 Thereafter 2,861 — Total Minimum Lease Payments 9,357 387 Imputed Interest (1,397) (44) Total $ 7,960 $ 343 |
Schedule of Finance Lease Maturity | Future minimum lease payments under non-cancelable leases as of January 31, 2022, excluding the future minimum lease payments for those leases that have not yet commenced as of January 31, 2022, were as follows: Operating Financing Remainder of fiscal 2022 $ 497 $ 62 2023 1,842 86 2024 1,485 86 2025 1,441 86 2026 1,231 67 Thereafter 2,861 — Total Minimum Lease Payments 9,357 387 Imputed Interest (1,397) (44) Total $ 7,960 $ 343 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 9 Months Ended |
Jan. 31, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands): Three Months Ended Nine Months Ended January 31, 2022 January 31, 2021 January 31, 2022 January 31, 2021 Basic 2,790 2,762 2,785 2,759 Dilutive effect of stock options and RSUs — 27 — — Weighted average common shares outstanding - diluted 2,790 2,789 2,785 2,759 |
Defined Benefit Pension Plans (
Defined Benefit Pension Plans (Tables) | 9 Months Ended |
Jan. 31, 2022 | |
Retirement Benefits [Abstract] | |
Pension Expenses | Pension (income) / expense consisted of the following (in thousands): Three Months Ended January 31, 2022 January 31, 2021 Service cost $ 0 $ 0 Interest cost 177 181 Expected return on plan assets (401) (321) Recognition of net loss 136 428 Net periodic pension (income) expense $ (88) $ 288 Nine Months Ended January 31, 2022 January 31, 2021 Service cost $ 0 $ 0 Interest cost 531 543 Expected return on plan assets (1,203) (963) Recognition of net loss 406 1,285 Net periodic pension (income) expense $ (266) $ 865 |
Segment Information (Tables)
Segment Information (Tables) | 9 Months Ended |
Jan. 31, 2022 | |
Segment Reporting [Abstract] | |
Segment Information | The following tables provide financial information by business segments for the periods ended January 31, 2022 and 2021 (in thousands): Domestic International Corporate / Total Three months ended January 31, 2022 Revenues from external customers $ 29,531 $ 11,102 $ — $ 40,633 Intersegment revenues 194 1,136 (1,330) — Earnings (loss) before income taxes (255) 869 (1,501) (887) Three months ended January 31, 2021 Revenues from external customers $ 25,066 $ 8,273 $ — $ 33,339 Intersegment revenues 463 550 (1,013) — Earnings (loss) before income taxes 206 689 (1,613) (718) Domestic International Corporate / Total Nine Months Ended January 31, 2022 Revenues from external customers $ 89,128 $ 30,029 $ — $ 119,157 Intersegment revenues 539 2,272 (2,811) — Earnings (loss) before income taxes (2,559) 2,111 (4,382) (4,830) Nine Months Ended January 31, 2021 Revenues from external customers $ 83,896 $ 24,866 $ — $ 108,762 Intersegment revenues 1,715 2,460 (4,175) — Earnings (loss) before income taxes 1,794 1,610 (5,071) (1,667) |
Cash, Cash Equivalents and Re_3
Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands | Jan. 31, 2022 | Apr. 30, 2021 | Jan. 31, 2021 | Apr. 30, 2020 |
Cash and Cash Equivalents [Abstract] | ||||
Cash and cash equivalents | $ 4,697 | $ 5,206 | ||
Restricted cash | 805 | 525 | ||
Total cash, cash equivalents and restricted cash | $ 5,502 | $ 5,731 | $ 6,103 | $ 5,215 |
Revenue Recognition - Summary o
Revenue Recognition - Summary of Net Sales Transferred to Customers at a Point in Time and Over Time (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | |
Disaggregation of Revenue [Line Items] | ||||
Total | $ 40,633 | $ 33,339 | $ 119,157 | $ 108,762 |
Over Time | ||||
Disaggregation of Revenue [Line Items] | ||||
Total | 39,342 | 32,471 | 115,371 | 106,072 |
Point in Time | ||||
Disaggregation of Revenue [Line Items] | ||||
Total | 1,291 | 868 | 3,786 | 2,690 |
Domestic | ||||
Disaggregation of Revenue [Line Items] | ||||
Total | 29,531 | 25,066 | 89,128 | 83,896 |
Domestic | Over Time | ||||
Disaggregation of Revenue [Line Items] | ||||
Total | 28,240 | 24,198 | 85,342 | 81,206 |
Domestic | Point in Time | ||||
Disaggregation of Revenue [Line Items] | ||||
Total | 1,291 | 868 | 3,786 | 2,690 |
International | ||||
Disaggregation of Revenue [Line Items] | ||||
Total | 11,102 | 8,273 | 30,029 | 24,866 |
International | Over Time | ||||
Disaggregation of Revenue [Line Items] | ||||
Total | 11,102 | 8,273 | 30,029 | 24,866 |
International | Point in Time | ||||
Disaggregation of Revenue [Line Items] | ||||
Total | $ 0 | $ 0 | $ 0 | $ 0 |
Revenue Recognition - Additiona
Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Jan. 31, 2022 | Apr. 30, 2021 | |
Disaggregation of Revenue [Line Items] | ||
Contract liabilities | $ 3,104 | $ 3,123 |
Contract liability recognized as revenue percentage | 100.00% | 100.00% |
Accounts receivable | ||
Disaggregation of Revenue [Line Items] | ||
Contract assets | $ 8,450 | $ 5,716 |
Other assets | ||
Disaggregation of Revenue [Line Items] | ||
Contract assets | $ 1,305 | $ 1,213 |
Inventories - Summary of Invent
Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands | Jan. 31, 2022 | Apr. 30, 2021 |
Inventory Disclosure [Abstract] | ||
Finished products | $ 4,997 | $ 2,988 |
Work in process | 2,837 | 1,832 |
Raw materials | 12,113 | 11,697 |
Total | $ 19,947 | $ 16,517 |
Inventories - Additional Inform
Inventories - Additional Information (Detail) - USD ($) $ in Thousands | Jan. 31, 2022 | Apr. 30, 2021 |
Inventory [Line Items] | ||
Inventories | $ 19,947 | $ 16,517 |
International Subsidiaries | ||
Inventory [Line Items] | ||
Inventories | $ 2,238 | $ 2,560 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis (Detail) $ in Thousands | Jan. 31, 2022USD ($)CompensationPlan | Apr. 30, 2021USD ($)CompensationPlan |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | $ 2,715 | $ 2,757 |
Financial Liabilities | $ 3,164 | $ 3,169 |
Number of non-qualified compensation plans maintained | CompensationPlan | 2 | 2 |
Non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Liabilities | $ 3,164 | $ 3,169 |
Trading securities held in non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,274 | 1,299 |
Cash surrender value of life insurance policies | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,441 | 1,458 |
Level 1 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,274 | 1,299 |
Financial Liabilities | 0 | 0 |
Level 1 | Non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Liabilities | 0 | 0 |
Level 1 | Trading securities held in non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,274 | 1,299 |
Level 1 | Cash surrender value of life insurance policies | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 0 | 0 |
Level 2 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,441 | 1,458 |
Financial Liabilities | 3,164 | 3,169 |
Level 2 | Non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Liabilities | 3,164 | 3,169 |
Level 2 | Trading securities held in non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 0 | 0 |
Level 2 | Cash surrender value of life insurance policies | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | $ 1,441 | $ 1,458 |
Long-term Debt and Other Cred_2
Long-term Debt and Other Credit Arrangements (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Jan. 31, 2022 | Jul. 30, 2021 | Apr. 30, 2021 | |
Debt Instrument [Line Items] | |||
Remaining borrowing capacity | $ 4,100 | $ 7,500 | |
Minimum monthly liquidity covenant requirement | $ 2,000 | ||
Minimum Supplemental Liquidity covenant requirement, through calendar year 2021 | 1,000 | ||
Minimum Supplemental Liquidity covenant requirement, thereafter calendar year 2021 | $ 1,500 | ||
Supplemental liquidity covenant threshold | 3,000 | ||
Advance Amount One | |||
Debt Instrument [Line Items] | |||
Outstanding advances under the long-term debt | 8,400 | 6,800 | |
Advance Amount Two | |||
Debt Instrument [Line Items] | |||
Outstanding advances under the long-term debt | $ 704 | $ 704 |
Leases - Additional Information
Leases - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | Apr. 30, 2021 | |
Leases [Abstract] | |||||
Right of use assets | $ 8,006 | $ 8,006 | $ 9,279 | ||
Operating cash paid to settle lease liabilities | $ 1,515 | $ 1,299 | |||
Remaining lease term (in years) | 8 years | ||||
Option to extend, term (in years) | 5 years | ||||
Option to terminate, term (in years) | 1 year | ||||
Operating lease, expense | 754 | $ 718 | $ 2,309 | 2,032 | |
Operating lease, short term, expense | $ 245 | $ 267 | $ 794 | $ 733 | |
Weighted average remaining lease term, operating lease (in years) | 5 years 7 months 6 days | 5 years 7 months 6 days | |||
Weighted average discount rate, operating lease | 4.10% | 4.10% | |||
Weighted average remaining lease term, finance lease (in years) | 4 years 7 months 6 days | 4 years 7 months 6 days | |||
Weighted average discount rate, finance lease | 6.80% | 6.80% |
Leases - Schedule of Operating
Leases - Schedule of Operating and Finance Lease Maturity (Details) $ in Thousands | Jan. 31, 2022USD ($) |
Operating Leases, After Adoption of 842: | |
Remainder of fiscal 2022 | $ 497 |
2023 | 1,842 |
2024 | 1,485 |
2025 | 1,441 |
2026 | 1,231 |
Thereafter | 2,861 |
Total Minimum Lease Payments | 9,357 |
Imputed Interest | (1,397) |
Total | 7,960 |
Financing Leases, After Adoption of 842: | |
Remainder of fiscal 2022 | 62 |
2023 | 86 |
2024 | 86 |
2025 | 86 |
2026 | 67 |
Thereafter | 0 |
Total Minimum Lease Payments | 387 |
Imputed Interest | (44) |
Total | $ 343 |
Earnings Per Share - Additional
Earnings Per Share - Additional Information (Detail) - shares | 9 Months Ended | |
Jan. 31, 2022 | Jan. 31, 2021 | |
Earnings Per Share [Abstract] | ||
Anti-dilutive options exclude from computation of earning per share (in shares) | 135,435 | 83,910 |
Earnings Per Share Schedule of
Earnings Per Share Schedule of Earnings Per Common Share (Details) - shares shares in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | |
Weighted average number of common shares outstanding | ||||
Basic (in shares) | 2,790 | 2,762 | 2,785 | 2,759 |
Dilutive effect of stock options and RSUs (in shares) | 0 | 27 | 0 | 0 |
Weighted average common shares outstanding - diluted (in shares) | 2,790 | 2,789 | 2,785 | 2,759 |
Stock Options and Stock-Based_2
Stock Options and Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||
Jun. 30, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Directors' fees paid with shares of common stock in lieu of cash in accordance with Director compensation guidelines | $ 41 | $ 41 | |||
2017 Plan | Restricted Stock Units (RSUs) | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock-based compensation expense | $ 109 | $ 129 | 433 | $ 344 | |
Remaining estimated compensation expense | $ 907 | $ 907 | |||
2017 Plan | Restricted Stock Units (RSUs) | Tranche One | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Restricted stock units granted (in shares) | 5,500 | ||||
Vesting period (in years) | 2 years | ||||
2017 Plan | Restricted Stock Units (RSUs) | Tranche Two | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Restricted stock units granted (in shares) | 51,471 | ||||
Vesting period (in years) | 3 years |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | Apr. 30, 2021 | |
Income Tax Disclosure [Abstract] | |||||
Income tax expense (benefit) | $ 399 | $ (813) | $ 845 | $ (989) | |
Effective income tax rate | (45.00%) | 113.20% | (17.50%) | 59.30% | |
Deferred tax liability, global tax exposure for unremitted earnings of international subsidiaries | $ 895 | $ 895 | $ 776 |
Defined Benefit Pension Plans -
Defined Benefit Pension Plans - Additional Information (Detail) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | |
Retirement Benefits [Abstract] | ||||
Employer contributions | $ 0 | $ 0 | $ 0 | $ 0 |
Assumed as expected long-term rate of return (as a percent) | 7.75% | 7.75% |
Defined Benefit Pension Plans_2
Defined Benefit Pension Plans - Pension Expenses (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | |
Retirement Benefits [Abstract] | ||||
Service cost | $ 0 | $ 0 | $ 0 | $ 0 |
Interest cost | 177 | 181 | 531 | 543 |
Expected return on plan assets | (401) | (321) | (1,203) | (963) |
Recognition of net loss | 136 | 428 | 406 | 1,285 |
Net periodic pension (income) expense | $ (88) | $ 288 | $ (266) | $ 865 |
Segment Information - Additiona
Segment Information - Additional Information (Detail) | 9 Months Ended |
Jan. 31, 2022Segment | |
Segment Reporting [Abstract] | |
Number of business segments | 2 |
Segment Information (Details)
Segment Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 31, 2022 | Jan. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021 | |
Segment Reporting Information [Line Items] | ||||
Net sales | $ 40,633 | $ 33,339 | $ 119,157 | $ 108,762 |
Intersegment revenues | 0 | 0 | 0 | 0 |
Earnings (loss) before income taxes | (887) | (718) | (4,830) | (1,667) |
Corporate / Eliminations | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 0 | 0 | 0 | 0 |
Intersegment revenues | (1,330) | (1,013) | (2,811) | (4,175) |
Earnings (loss) before income taxes | (1,501) | (1,613) | (4,382) | (5,071) |
Domestic Operations | Operating Segments | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 29,531 | 25,066 | 89,128 | 83,896 |
Intersegment revenues | 194 | 463 | 539 | 1,715 |
Earnings (loss) before income taxes | (255) | 206 | (2,559) | 1,794 |
International Operations | Operating Segments | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 11,102 | 8,273 | 30,029 | 24,866 |
Intersegment revenues | 1,136 | 550 | 2,272 | 2,460 |
Earnings (loss) before income taxes | $ 869 | $ 689 | $ 2,111 | $ 1,610 |